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Abstract
REVIEW OF THE p53 TUMOR SUPPRESSOR GENE
AND ITS ROLE IN GLIOMAS
James Dearing Christian IV
A thesis submitted in partial fulfillment of the
requirements for the degree of Master of Science at Virginia
Commonwealth University.
Virginia Commonwealth University, 1994.
Major Director: Dr. Randall Merchant, Ph.D.
Department of Anatomy
The following review of the p53 tumor suppressor gene
will be discussed with particular attention to its role in
human gliomas,

as well as the various advances that have

brought this molecule to the forefront of cancer research.

A

review of tumorigenesis focuses on the molecular mechanisms
that convey neoplastic characteristics upon a normal cell. It
is

discussed

how

the

coordinate

advances

in

chromosome

analysis and molecular techniques enabled the p53 gene to be
categorized as a "tumor suppressor gene" and applied to
various

forms

of

cancer,

including

colorectal

and

lung

carcinoma. The focus of the review will be on the involvement
of p53 in gliomas, as the p53 mutation rate in gliomas is
quite different from that in other cancers.

It is also noted

how cellular characteristics. contribute to the function of
p53,

and how p53

expression indicates grades of tumor

X

malignancy, thereby aiding in diagnosis and prognosis.

In

conclusion, future applications of p53 in areas such as gene
therapy are examined, as well as alternative mechanisms of
tumor suppression that circumvent direct p53 mutations in
gliomas.

Introduction
Tumors of neuronal or glial cell origin are termed
neuroepithelial tumors,

and they represent fifty to sixty

percent of primary intracranial tumors (Annegers et al. , 1981;
Walker,

1985).

neuroectoderm,

These cells have their origin from the
which distinguishes their tumors from other

cancers associated with soft cell tissue (sarcomas) derived
from the mesoderm.

The World Health Organization (WHO) has

divided gliomas, tumors of glial cell origin, into different
grades based on their cytological characteristics such as
degree of cellularity, mitoses, and necrosis.

The current

system uses a three-stage classification method,
gliomas into astrocytoma, anaplastic astrocytoma

dividing
(AA),

and

glioblastoma multiforme (GBM) (Okazaki and Scheithauer, 1988).
There is also a four-stage sytem that has been used for many
years and divides gliomas into malignancy grades I-IV, with
grade IV being the most malignant.

Due to the prevalence of

the four-stage system used in the majority of the literature,
it is this sytem that will be followed in this review.
is the Grade I juvenile pilocytic astrocytoma,
astrocytoma,

Grade III AA,

Scheithauer, 1988) .

and Grade IV GBM

There

Grade II

(Okazaki and

The natural history for those gliomas

presenting as low grade is that they classically progress to
l

high grade tumors.
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The method by which this progression

occurs is disputed.

It is possible that GBM develops by

neoplasia (new growth) from a glioblast cell, but these cells
have not been found in adults.

Therefore, it is more likely

that GBM develops by anaplasia (loss of differentiation) of
astrocytes

in

astrocytomas

and

then

AA's,

eventually

proceeding to GBM (Russell and Rubinstein, 1989}.
There

are

incidence,

several disturbing

particularly gliomas,

trends

in

brain

tumor

that indicate a need for

immediate attention to this form of cancer.

For instance,

brain tumors seem to be affecting younger populations than was
originally observed.

Brain tumors rank second in cancer

incidence for children,
among

young

adults

fifth for adolescents,

(Beardsley,

and €ighth

Still,

1994).

other

epidemiological statistics indicate that older populations
show increasing incidence of brain tumors as well (Marantz and
Walsh,

1994).

tumors,
exposure

as

Also, there is no known etiology for brain

skin

and

cancer is causally associated

lung

cancer

with

smoking.

with
Of

sun

adult

neuroepithelial tumors, GBM is the most commonly occurring at
initial diagnosis, accounting for approximately fifty percent
of

the

tumors

classified

as

(Zimmerman 1969; Walker et al.,

this

highest

grade

glioma

1985; Green et al.,

1976).

Equally discouraging factors involved with gliomas are the
limited
period.

effective treatment available and

short

survival

Conventional treatment for GBM, including radical

3

resection and radiation therapy, typically provides a median
survival of about nine months with less than five percent
surviving five years after the initial diagnosis (Salcman,
1990).

Adjuvant

immunotherapy,

have

therapies,

including

not yet

been shown

chemotherapy
to

increase survival over conventional treatment.

and

significantly
Therefore, the

need for innovative therapies for gliomas is evident.
The inactivation of the p53 protein is believed to be a
crucial step in the process of tumorigenesis in many cancers,
including colorectal, breast, lung, and brain (Nigro et al.,
1989).

Due the malignant nature of these cancers, especially

GBM, the involvement of p53 as a tumor suppressor gene has
been studied with increased attention.

Reintroduction of p53

into cells deficient for this tumor suppressor gene has been
shown to largely reverse the malignant phenotype.
observations

raise

the

possible

utility _ of

reintroduction as a therapeutic maneuver.

These

attempting

In this way, the

p53 tumor suppressor gene offers a unique opportunity for gene
therapy treatment of brain tumors and other cancers.

The goal

of this review is to offer insight into the nature of the p53
tumor suppressor gene and the basis for its potential role in
the treatment of gliomas.

Review of Tumorigenesis
Tumorigenesis is the process by which a normal cell
deviates from its typical pattern of development and attains
a distinct cancerous phenotype.

Characteristics of this stage

include uncontrolled growth and invasiveness, with development
and

differentiation

also

being

adversely

affected.

Uncontrolled growth is required for all cancer development,
while these other qualities apply to specific ones.

Cancers

such as colon, lung, and breast are characterized by their
metastatic potential, while gliomas are particularly noted for
their invasiveness.

Cells typically develop through signals

from their extracellular environment, and if the reception of
these signals is altered, the cells may grow in an abnormal
manner.

In the same way, cells begin to differentiate at a

certain stage, and if this is negatively affected, a loss of
differentiation

may

Cancer

occur.

formation

involves

a

complex array of factors, with potential results that can be
quite damaging to the normal functions of a cell.
A selective growth advantage within cancer cells allows
them

to

undergo

multistage,
lesions.

clonal

expansion.

Tumorigenesis

is

a

stepwise process that involves several genetic

In order for the correct mechanisms to occur, there

must be an interplay between two principal participants,
4
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including

oncogenes

genes).

The

and

critical

anti-oncogenes
interaction

is

(tumor
the

suppressor

activation

of

oncogenes by a variety of mechanisms and the inactivation of
tumor suppressor genes, such as by a single missense mutation
as with p53.

The role of p53 is apparent as each of these

classes of genes is further examined.
Oncogenes represent an altered version of proto-oncogenes
(normal cellular counterparts of oncogenes), and they have the
ability to transform cells in tissue culture (in vitro) and
render them tumorigenic in vivo (Cantley et al., 1991; Bishop,
1991; Hunter, 1991).

Many oncogenes were identified within

genomes of acutely transforming retroviruses.

These viruses

evolve through genetic recombination such that a mutated
version of a cellular proto-oncogene is integrated into a
partially deleted retroviral genome (Bishop, 1983). Oncogenes
may

be

activated

mechanisms,

including

retroviruses,
segments,

by

a

number

of

different

transduction

of

molecular

oncogenes

by

translocation of chromosomes or chromosomal

gene

amplification,

deletion

regulatory genes, and point mutations.

of

suppressor

or

The two most common

mechanisms of oncogene activation'include: 1) mutations of the
gene itself, the enhancer, promoter, or regulatory gene, which
result in altered function;

2) displacement of a gene by

random breakage so that it is downstream of an inappropriate
promoter,

resulting in altered expression.

To test the

identity of a gene as an oncogene, the candidate gene is

introduced
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into a normal cell and if the cell acquires

cancerous traits,
(Bishop,

1985).

then the introduced gene is an oncogene
In order to better understand the role of

oncogenes in tumorigenesis, it is necessary to examine their
mechanisms of transformation of normal cells into cancerous
ones.
The mechanism of oncogene action relies on its disruption
of the normal function of proto-oncogenes.

A normal cell

within tissue is predominantly under the control of its
surroundings,

which send various messages that affect the

cell's growth and division in different ways.

These signals

are conveyed by growth factors and may be growth-stimulatory
or growth-inhibitory in nature.

Proto-oncogenes encode many

of the proteins in the complex signaling circuitry that
enables a normal cell to respond to extracellular growth
factors (Weinberg, 1994).

These proteins can include: cell

surface receptors, cytoplasmic signal transducers, and nuclear
transcription factors.

The nuclear transcription factors,

upon

the

stimulation

from

other

proteins,

activate

cellular genes that coordinate the cell's growth pattern.
is

from

oncogenes

proto-oncogene
receive

proteins

their function,

such
for

as

these

upon

the
It

that

the

mutation

the

oncogenes are able to express aberrantly functioning versions
of these proteins.

In this way, oncogene proteins can then

activate the signaling circuits within the cell in the absence
of stimulation by extracellular growth factors

(Weinberg,

1994).
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Oncogenes can thereby ceaselessly drive cell growth,

for the cells divide despite the presence of the appropriate
signals.

However, as a protective mechanism, the creation of

a cancer cell is more complex, and multiple genetic changes
must take place for tumorigenesis to occur.

Oncogenes are

only one of the factors needed to complete the process of
tumorigenesis, as anti-oncogenes (tumor suppressor genes) must
also be deleted or mutated.
Tumor suppressor genes have not been studied to the
extent that oncogenes have, but their importance in the scheme
of tumor formation is equally apparent.
examples

of

cloned

tumor

suppressor

association and chromosome affected.

Table 1 offers
genes

with

tumor

Normal cells possess

genes that not only stimulate growth as proto-oncogenes do,
but also act to constrain growth, as is the case with tumor
suppressor genes. Cells therefore receive not only growth
stimulatory signals (received by proto-oncogene proteins), but
also growth-inhibitory signals (received by proteins specified
by tumor suppressor genes).

If the function of the tumor

suppressor gene is inactivated and therefore its protein
expression altered, then the cell cannot correctly respond to
extracellular

growth-inhibitory

signals.

The

cells

will

divide continually because there are no proper receptors for
the negative growth signals to be received and transduced.

In

the case of a cancer cell, the oncogenes become hyperactivated
versions of the proto-oncogenes, and there is a coordinate

8

Table 1.

Examples of Cloned Tumor Suppressor Genes

Tumor Suppressor
Gene

Tumor

Chromosome
Affected

Rb

retinoblastoma
lung carcinoma
(small-cell)
osteosarcomas

13ql4

p53

carcinomas:colorectal
lung
breast
leukemias
gliomas

17pl3.1

NFl

neurofibromas

17qll

NF2

Schwannomas
meningiomas

22q

9
loss of tumor suppressor gene function due to deletion.
effect,

a cancer cell's growth may derive from

In

a stuck

accelerator (an activated oncogene) or a defective braking
system (inactivated tumor suppressor gene), and both defects
together are thought to be needed to achieve truly aggressive
proliferation (Weinberg, 1994).
An initial model of tumor suppressor genes was proposed
by Knudson (1969) and subsequently investigated by Friend et
al.

(1986) and

Fung et al.

(1987) in the study of the

retinoblastoma (Rb) gene in neuroblastoma.

The Rb gene was

the first tumor suppressor gene cloned and still represents
the classic example of a tumor suppressor gene.

The existence

of the Rb tumor suppressor gene was originally predicted by a
statistical study of congenital Rb.

Knudson (1971) based his

proposal on the observations of 48 cases of congenital Rb, a
cancer of the eye in children, arguing that Rb arises by two
mutational events.

In the dominantly inherited form,

the

first mutation is inherited via germline transmission and the
second occurs as a spontaneous mutation in somatic cells.

In

the nonhereditary form, two spontaneous mutations must occur
in somatic cells.

His theory about cancer originating in more

than one discreet stage was original, but the mechanism by
which cancer could arise in as few as two steps remained
unclear.
Friend et al.

(1986) first succeeded in cloning the Rb

gene, after other researchers such as Lee et al.

(1987) -had

10
identified the general location of Rb on chromosome 13.
et al.

Lee

(1987) by cloning and sequence analysis actually

isolated and sequenced the human Rb susceptibility gene,
thereby allowing true studies of mutations to be done.

It was

noted from earlier studies that a genetic locus in chromosome
region 13q14 conferred susceptibility to Rb.

on the basis of

chromosomal location, homozygous deletion, and tumor-specific
changes in expression, Rb susceptibility gene was identified
as a 200-Kb gene that encodes a 105-kilodalton (KD) nuclear
phosphoprotein

(Lee et al.,

1987).

In

Rb,

there is a

deletion on the long arm of chromosome 13, with subsequent
loss or inactivation of the gene.

Subsequently, it was shown

that the Rb gene forms stable complexes with
of the ElA adenovirus

(Whyte et al.,

the oncoprotein

1988),

the large T

antigen (the transforming protein of the SV4-0 virus) (Ludlow
et al.,

1989),

and the human papillomavirus type 16

oncoprotein (Dyson et al., 1989).

E7

The fact that transforming

proteins encoded by DNA tumor viruses bind to the Rb-encoded
protein suggested that these viral proteins may function
through inactivation of the Rb tumor suppressor gene product.
Inactivation of both alleles at'the Rb locus during retinal
development is the primary mechanism of tumorigenesis in this
cancer.
The mutant versions of the Rb gene act as "simple
recessive" alleles (Weinberg, 1994).

The gene is present in

two copies, and if one is lost, cell growth remains normal

based on the remaining gene copy.
"knocked

out",

then

abnormal

l-1

If the second copy is

proliferation

occurs.

The

chances of losing one copy of a gene are as low as one in a
million per cell generation; the chance of losing both copies
is less than about one in a billion per cell generation
(Weinberg, 1994).
genetic

This Rb tumor suppressor model of recessive

mechanisms can

be contrasted with

negative" effect of p53 in other cancers.

the

"dominant

In the case of p53,

the initially mutated gene copy loses its tumor-suppressing
function by deletion and simultaneously interferes with the
function of the remaining intact copy (Weinberg, 1994).
normal

This

(wild-type) copy may either be deleted entirely or

replaced with another copy of the mutant version.

Therefore,

the mutant p53 gene adversely affects the functions of the
normal gene copy, which may result in abnormal growth.

In

this way, the mechanism of inactivation of the Rb gene is
different from that of p53.
Nevertheless, other Rb characteristics are quite similar
to those of p53.

In a definitive study by Fung et al. (1993),

it was shown that inactivation of both alleles of the Rb gene
by mutation resulted in a predisposition to development of
this cancer.

Furthermore, growth arrest could be reinstated

by transfection of an exogeneous wild-type Rb gene.

Also, the

inactive Rb gene was shown to be passed down in a familial
context.

These early studies involving the Rb gene enabled

the eventual p53 model of tumor suppression to be realized.

Identification of p53
The discovery of p53 is credited by two different groups
of experimenters.

Lane and Crawford (1979) immunoprecipitated

a cellular 53-KD nuclear phosphoprotein bound to the large
transforming T antigen of the SV40 (simian virus 40) DNA tumor
virus.

A closely related study by Linzer and Levine (1979)

characterized a 54-KD cellular SV40 tumor antigen in SV40transformed cells.

Originally, it was postulated that perhaps

the p53 protein could be a viral protein because of its
interaction with the SV40 DNA virus, but p53 could not be
found in the viral genome.

It was not until the p53 protein

was found in the nucleus of the cell that subsequent advances
could be made.

Since these experiments, the understanding of

the role of p53 in the process of tumorigenesis has continued
to

evolve,

and

it

is

only recently

that

p53

has

been

It was subsequently

classified as a tumor suppressor gene.

proposed that p53 was an oncogene because it could cooperate
with the "ras" oncogene in transformation
1984) .

It is now known,

however,

(Parada et al.,

that mutant p53 gene

derivatives were used in those early experiments.

P53 was

later

It

examined

in

clones

of

non-tumor

cells.

was

discovered that the p53 sequence in these non-tumor cells was
not the same as that previously studied.
12

In fact, experiments

n
proved that wild-type p53 does not associate with "ras" to
transform primary cells unless a mutation has taken place
(Hinds et al., 1989).

It was then suggested that the p53 in

normal cells was the wild-type p53, while the mutant p53 was
associated with the ras oncogene in co-transformation (Hinds
et al.,1989).

Further studies indicated that indeed the p53

protein could not be an oncogene, for although the mutant form
was found in tumors, the wild-type protein was found to
suppress tumor progression (Mercer et al., 1990).

It was at

this time that p53 began to be considered a tumor suppressor
gene based on its comparisons with the Rb gene model.
Mutations in a variety of locations on the p53 gene are
responsible for the transforming potential of the molecule,
which is coordinated with an inactivation of wild-type p53.
Mutations of the p53 gene have been noted in a series of
experiments over the years, but it was not until there was a
correlation with chromosomal abnormalities associated with a
variety

of

cancers

suppressor gene.
associated

p53

became

viewed

as

a

tumor

Subsequently, the role of p53 and its

proteins

including gliomas.

that
has

been

studied

in

many

cancers,

Over time, various characterizations of

p53 have been made, thereby enabling researchers to better
understand the true nature of this molecule.

Association of Cancers with Characteristic Chromosomal and
Molecular Genetic Abnormalities
With the advent of chromosome banding techniques in 1970
by Caspersson and Zech (Mitelman,1994), cancer cytogenetics
Each chromosome could be identified on

was revolutionized.
the

basis

of

its

distinct

banding

pattern,

and

all

descriptions of chromosomal deviations became more precise.
Hematalogical
1980's,

malignancies

solid

tumors

and,

began

to

associated chromosomal aberrations.

subsequently
be

examined

during
for

the

cancer

Chromosome changes could

be numerical, where whole chromosomes were added or deleted,
or

structural

changes,

which

translocations,

involved

deletions, inversions, and insertions (Sandberg, 1994).
concordance

with

these

cytogenetic

breakthroughs,

In
new

molecular genetic techniques were also discovered that enabled
researchers

to

investigate tumor

cells

at

the

level

of

individual genes (Mitelman, 1994).
Advances in molecular genetics were beginning to offer
insight into the detailed mechanisms of neoplastic behavior.
Novel molecular analyses included: detection of changes in DNA
(Restriction Fragment Length Polymorphism (RFLP), Polymerase
Chain Reaction (PCR) amplification, and Southern Blotting),
messenger RNA (mRNA) (Northern Blotting), and protein products
14
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(Western Blotting) (Sandberg, 1994).
include

full

sequencing

polymorphism (SSCP}.

and

Other current advances

single-strand

conformation

The instances when particular techniques

are used are based on the particular aims of the experiment
and the strengths and weaknesses of each technique.

For

example, in the case of RFLP, a mutation at the restriction
cut-site or a deletion of a cut fragment will result is
absence of detection by a probe.

SSCP is much more sensitive

than RFLP because it can detect changes in single base pairs
as opposed to whole fragments.

However, SSCP requires that

the cells of interest be in a proportion of at least 10% of
the sample, otherwise they are too diluted to be detected.
RFLP

is

particularly

effective

heterozygosity on chromosomes.

in

detecting

loss

of

Normally, both copies of a

gene will have different lengths when detected by RFLP; in
other words, heterozygosity is observed.
a

mutation

of

one

allele

and

a

However, if there is

subsequent

deletion

or

replacement of the other allele with a mutant copy, only one
band will appear by RFLP.

Therefore, loss of heterozygosity

has occurred and has been detected by RFLP.

Advances such as

these in molecular genetics raise the possibility of aiding in
more effective diagnosis and prognosis of certain cancers and
their associated abnormalities.
At about the same time p53 was becoming a new area of
interest in cancer research,
molecular

gene

analysis

advances in cytogenetics and
were

demonstrating·

specific

16

chromosomal and submicroscopic abnormalities in association
with

various

Of

cancers.

particular

interest

were

the

abnormalities associated with colorectal and lung carcinoma.
The chromosomal changes associated with these cancers had been
studied for years, but it was a few select experiments that
linked these mutations to effects on the inactivation of the
p53 gene in gliomas.
Colorectal carcinoma
Colorectal carcinomas appear to arise from adenomas in a
stepwise manner. These different stages parallel the clinical
pattern of tumor progression.

Vogelstein et al.

(1988)

examined 172 colorectal tumor specimens, representing various
stages of neoplastic development for four genetic alterations
(ras-gene mutations and allelic deletions of chromosomes 5,
17, and 18).

In terms of relevance to p53, it is important to

note that chromosome 17p sequences were lost in about seventy
These

five percent of the carcinomas examined.

results

indicate a stepwise model of colorectal tumor development in
which

both

activation

inactivation
of

oncogenes

of

tumor

suppressor

are

required

for

genes

and

tumorigenesis.

(Vogelstein et al., 1988).
Kern

at

al.

(1989)

also reported

specific

genetic

mutations on the short arm of chromosome 17 occurring. in
colorectal carcinoma.

In their study, colorectal carcinomas

17
from eighty-three patients were examined for molecular genetic
alterations.

Allelic deletions of specific chromosomal arms,

including the short arm of 17 (p) and long arm of 18 (q), were
Deletions of 17p and 18g correlated greatly

both reported.

with the development of distant metastasis and cancer-related
death (Kern et al., 1989), possibly indicating a novel method
of diagnosis for certain types of cancer.
Based on these two experiments, Baker et al. (1989) were
beginning to associate 17p deletions with p53 gene mutations
in colorectal carcinomas, thereby arguing for a role of p53 in
this cancer.

The common area of deletion in these tumors was

localized to a region contained within bands 17pl2 to 17p13.3,
to which the p53 gene is mapped (Baker et al., 1989).
coding

regions

were

then

analyzed

from

P53

tumors

two

characterized as having allelic deletions of chromosome 17p
and expression of large amounts of p53 mRNA from the remaining
allele. This remaining allele was found to be mutated in each
of these two tumors.

Both mutations occurred in a highly

conserved region of the p53 gene previously found to contain
alterations.
neoplasia

Baker et al. (1989) suggested that colorectal

might

develop

from'

p53

gene

mutations

that

inactivate a tumor suppressor function of the normal p53 gene.
The experiment to prove the tumor suppressor function of
p53 in colorectal carcinoma was also performed by Baker et al.
(1990).

It

had

been

noted

that

in

colorectal

cancer,

mutations of the p53 gene happened in coordination with a

deletion of the remaining wild-type p53 allele.
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In this

study, wild-type and mutant human p53 genes were transfected
into human colorectal carcinoma cell lines.

Cells transfected

with the wild-type gene formed colonies five-to tenfold less
efficiently than those transfected with a mutant p53 gene
(Baker et al., 1990). Carcinoma cells with the wild-type gene
did not progress through the cell cycle.

This experiment

suggested that wild-type p53 gene can suppress the growth of
human colorectal carcinoma cells, and a mutation in the p53
gene product inhibits this suppressive ability (Baker et al.,
1990).
Lung carcinoma
As chromosomal alterations in colorectal carcinomas were
being

reported,

other

studies

mutations in lung carcinomas.

were

examining

chromosome

Loss of heterozygosity on

chromosomes 3, 13, and 17 in small-cell carcinoma was reported
by Yokota et al. (1987). Five different histological types of
lung cancers from forty-seven patients were analyzed for
possible loss of chromosomal heterozygosity.

In small-cell

carcinomas, loss of heterozygosity on 17p was seen in five of
five patients examined.

Based on this experiment and the

eventual mapping of the p53 gene to chromosome 17 (Nigro et
al., 1989), subsequent work would link p53 to the development
of lung cancer.
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The p53 gene was specifically examined in lung cancer by
Takahashi et al.

(1989) based in part on the chromosomal

alteration report by Yokota et al. (1987), but a correlation
between the cytogenetics and molecular genetics would not yet
be

firmly

In

established.

this

experiment,

genetic

abnormalities of p53 were seen to include homozygous deletions
and a variety of point or small mutations.

These mutations

changed the amino acid sequence in a highly conserved region
of the p53 open reading frame (Takahashi et al., 1989). Also,
low or absent p53 mRNA expression was observed in lung cancer
cell lines as compared to that in normal lung.
in

this

experiment

on

p53

mutations,

The work done

together

with

the

previous reports of chromosome 17 abnormalities, would serve
to strengthen the idea of p53 being a tumor suppressor gene.
In 1990, Iggo et al. studied the major histological types
of primary lung cancer for the expression of the p53 tumor
suppressor gene.

Abnormalities in p53 expression occurred in

twenty-eight of forty

(70%) lung carcinomas.

expression of mutant p53

Homozygous

mRNA was found to specifically

contain G to T transversions resulting in mis-sense mutations
(Iggo et al., 1990).

A similar, study reported mutations of

the p53 gene in primary, resected non-small cell lung cancer
(Chiba et al., 1990).

In this series, mutations changing the

p53 coding sequence were found in twenty-three of fifty-one
(40%) tumor specimens.

This indicates that the p53 gene and

chromosome 17 are important together in the tumorigenesis of
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lung cancer, although the direct connection was not made until
the same time as in gliomas.
Gliomas

Bigner et al. (1986) surveyed a large number of gliomas
for chromosomal alterations to determine areas of primary
gross

changes

in

glial

tumors.

Karyotypic

studies

of

malignant human gliomas showed the most common areas of change
were a gain of chromosome 7 or a loss of chromosomes 10 and
22.

Other chromosomes involved in rearrangements were 1, 6,

and 13.
Bigner et al. (1988) continued to study human malignant
gliomas for specific chromosomal abnormalities associated with
this particular cancer.

By karyotypic analysis of fifty-four

malignant human gliomas (forty-three GBM), gains of chromosome
7 and losses of chromosome 10 were seen (Bigner et al., 1988).
Structural abnormalities of 9p and 19g were statistically
significant as well.

Despite the ongoing characterization of

chromosomal abnormalities associated with glial tumors, no
connection could be made with the p53 tumor suppressor gene
because few abnormalities were detected in chromosome 17 at
this point.
Among the many chromosomal aberrations associated with
gliomas, abnormalities in chromosome 17 eventually were shown
in astrocytomas much like it had been identified in colorectal
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and lung carcinomas (James et al., 1989).

on

human

chromosome 17 from thirty-five patients with gliomas.

Eight

determine

combinations

allelic

of the twenty-four

at

RFLP was used to

seven

loci

(33%) tumors classified as astrocytic

showed a loss of constitutional heterozygosity at one or more
Therefore, the homozygosity for loci on chromosome 17p

loci.

could be associated with the development of glial tumors
(James et al., 1989).
Indicating that chromosomes such as 10 were not the only
loci undergoing loss of heterozygosity in human malignant
astrocytoma,

chromosome

17

was

abnormalities (Fults et al., 1989).
showed

a

similar

frequency

of

further

examined

RFLP of both AA and GBM
loss

of

constitutional

heterozygosity on chromosome 17 at forty percent.
17

was

becoming

particularly

for

important

Chromosome

because

of

its

relationship to p53.
A

link

between chromosome

17 and the p53 gene was

beginning to surface, as researchers realized that the loss or
inactivation of tumor suppressor genes could play a key role
in

the

onset

of

many

human cancers,

including

gliomas.

Further analysis of astrocytomas of various histological
malignancy grades took place by means of polymorphic DNA
markers.

This method improved the accuracy of detecting

chromosomal deletions over the standard cytogenetic technique
of karyotyping.

Potential loci containing tumor �uppressor

genes could be determined (El-Azouzi, 1989). Chromosomal loss
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or deletions were seen most frequently on the short arm of
chromosome

17

(fifty

percent

of

the

tumors),

and

these

deletions were observed in both low-grade and high-grade
astrocytomas.

The presence of these deletions in early stage

tumors indicated the possible involvement of chromosome 17 in
the initiation of tumor progression.

It is important to note

that the deletions on the short arm of chromosome 17 are
different

from

neurofibromatosis
chromosome 17.

the

gene

(NFl),

causing

which

maps

Von
to

the

Recklinghausen
long

arm

of

NFl was proposed at one time to be the leading

candidate as the most frequently mutated "tumor suppressor
gene" in a variety of cancers, when actually the one on the
short arm of chromosome 17, the location of the p53 gene,
would be more likely.

Characterization of p53 as a Tumor Suppressor Gene
It became apparent that the p53-encoding gene was not
only associated with tumorigenesis of colorectal carcinoma,
but also important in lung and brain cancers.

The critical

link between the p53 gene and the chromosome 17 alterations
associated with a number of different cancers was a study done
They sought to determine whether

by Nigro et al. (1989}.

tumors with allelic deletions of chromosome 17p contained
mutant

p53

genes

in

the

allele

retained,

characteristic of a tumor suppressor gene.

which

is

a

P53 sequences of

tumors derived from the colon, lung, brain, breast, and
mesenchyme were analyzed.

To examine p53 gene mutations, a

1,300 base-pair (bp) fragment including the entire p53 coding
region was generated from the complementary DNA (cDNA) using
PCR,

and this fragment was cloned and sequenced

entirety (Nigro et al., 1989}.

in its

Of the nineteen tumors with

allelic deletions of chromosome l 7p selected for sequence
analysis, thirteen contained a single missense mutation, and
two contained two missense mutations.

Therefore, most tumors

with one 17p allele contained a mutation of the p53 gene in
the remaining allele.

The "dominant negative" effect was

substantiated, in which the p53 gene is mutated in the process
of tumorigenesis, and through this effect is able to cause
23
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tumor progression by inactivating the remaining wild-type
allele.

In fact,

the "dominant negative" effect may be

mediated by binding of the mutant p53 product to the wild-type
product, creating an inactive oligomeric complex (Nigro et
al., 1989).
allele.

The mutant allele thereby inhibits the wild-type

The wild-type product remains in the cell, however,

and a further loss of growth control occurs when the wild-type
allele is deleted, leaving the cell with only a mutant allele.
Through this experiment, it was seen that most tumors with
chromosome 17p allelic deletions contain p53 point mutations
resulting in amino acid substitutions, and these mutations are
also found in some tumors that have retained both parental 17p
alleles. Also, the p53 gene mutations are "clustered" in four
distinct "hot-spot" regions which coincide with the most
highly conserved regions of the gene (exons 5-9) (Nigro et al.,
1989).

In this way, Nigro et al. (1989) linked the many

studies of chromosome 17 abnormalities seen in a variety of
cancers with the p53 gene mutations also seen in numerous
cancers.
Incidence in Human Cancer
Building
experimenters,

upon

this basis,

Levine et al.

two

subsequent

groups

of

(1991) and Hollstein et al.

(1991) were able to characterize the mutations of the p53 gene
as the most common genetic change in human cancers.

These

25

cancers

included:

esophagus,

colon,

reticuloendothelial
Transitions

tissues.

lung,

brain,

tissues,

predominated

breast,
and

liver,

hemopoietic

in colon,

brain,

and

lymphoid malignancies, whereas G:C to T:A transversions were
the most frequent substitutions seen in cancers of the lung
and liver (Hollstein et al., 1991).

Four specific regions of

the p53 protein within exons 5-9 were observed to contain the
majority of mutations: residues 117-142, 171-181, 234-258, and
270-286, all of which are highly conserved (Levine et al.,
1991).

There are also at least three mutation "hot spots,"

affecting residues 175, 248, and 273 (Levine et al., 1991).
Figure 1 shows the p53 open reading frame (amino acids 1-393)
with these hot spot and conserved regions.

Figure 1 also

shows those domains specified for DNA binding versus those for
transactivation function.

DNA binding occurs at the 3'

carboxyl terminus, whereas the transactivating function of the
p53 protein occurs at the 5' amino end.

The importance of

these regions will become clear as each of these areas is
discussed in subsequent sections.
It is essential to note that particularly in cancers of
the colon, lung, and breast, the mutation frequency rate of
the p53 gene can reach levels of nearly seventy percent. This
means

that

mutations resulting in

loss

of

p53

function

predispose the host to these cancers at a very high rate.
However, in gliomas, the mutation frequency rate of the p53
gene usually averages only about thirty percent.

This is
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consistent with the low values (forty percent) seen previously

for the rate of loss of heterozygosity of chromosome 17p in
gliomas (Fults et al., 1989), which maps for the p53 tumor
suppressor gene.

This suggests that the role of p53 in

gliomas may be different than that in other cancers.
It has been only recently that the relevance of the p53
protein

in

gliomas

has

begun

to

be

studied

in

detail.

However, it is important to note how p53 was correlated with
chromosomal abnormalities in other cancers such as colorectal
and

lung

carcinomas before it

was

seen

specifically

in

gliomas. This relationship to chromosomal aberrations allowed
the

p53

gene

to

be

associated

with

specific

cancers.

Subsequent advances examining the characteristics of the p53
protein allowed it to coordinately be reclassified as a tumor
suppressor gene instead of an oncogene.

This idea of tumor

suppression had been first postulated involving the Rb gene,
and then evidence specifically for the p53 tumor suppressor
gene

was

syndromes.

revealed,

including

associated

familial

cancer

The coordination of all of these efforts directs

the focus of p53 research into areas that demand immediate
attention, such as the highly malignant GBM.
Subsequent Advances in p53 Cellular Function
Since the characterization of the p53 gene .as a tumor
suppressor gene, several advances have been made that help
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explain the mechanisms by which the p53 gene performs its
Not all of these features apply specifically to

function.

gliomas, but an understanding of them aids in defining the
role of p53 in gliomas.
One of the first characteristics of p53 studied was its
ability

to

suppress

cellular

growth.

By

developing

a

temperature-sensitive mutant of p53, the reversibility of the
inhibition
examined

of

transformation

(Michalovitz

et

al.,

and

cell

proliferation

1990).

The

was

temperature

sensitive mutant, p53val135, induced transformation at 37.5°C
while at 32.5°C, it suppressed transformation, thereby acting
like wild-type p53 with its inhibition of proliferation of
transformed cells.
ability

of

Based upon a temperature shift,

wild-type

p53

apparently reversible.

to

suppress

transformation

the
is

This temperature-sensitive mutant

could therefore be used in subsequent experiments to study the
changing behavior of the p53 gene.
Using
exhibited

the

p53val135

increased

mutant,

nuclear

it

was

localization

shown
and

that

decreased

stability of the protein (Ginsberg et al., 1991).
experiment,

In this

p53val135 was used ,to show arrest of cellular

proliferation when overexpressed at 32.5°C.
temperature,

At this same

much of the p53 protein was located in the

nucleus and the p53val135 became destabilized.
however,

p53

the

p53

protein

was

located

At 37.5°C

primarily

in

the
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cytoplasm of proliferating cells, and the p53val135 was found
These observations suggest that the

in a more stable form.

function of p53 resides in the nucleus, and if it is removed
from this location, it no longer functions to suppress tumor
development.
Regarding the exact subcellular location of the p53
protein, Zerrahn et al. (1992) sought to further characterize
a basis for this localization.
temperature-sensitive

p53val135,

Previous work involved the
as

did

this

study

conjunction with the monoclonal antibody (mAb) PAb246.

in
The

purpose was to determine the status of the conformational
phenotype of the p53 protein at its different locations within
the cell.

P53 was examined in four cell lines, with cellular

phenotypes of normal (3T3), minimal transformant (T3T3), and
maximally transformed (3T3tx, Meth A).

P53 proteins in 3T3

and T3T3 were shown to react with PAb246, thereby indicating
a wild-type conformation, while the p53 in 3T3tx and Meth A
cells did not bind to the PAb246, thereby signalling a mutant
conformation.

By cell fractionation, a cytoplasmic location

of mutant p53 in 3T3tx and Meth A cells was determined, and by
immunofluorescence microscopic analysis, 3T3 and T3T3 were
localized to the cell nucleus (Zerrahn et al., 1992). In this
experiment,

cytoplasmic

and

nuclear

p53

of

the

phenotype bound to cellular heat shock proteins

mutant

(hsp) in

similar ratios, suggesting that hsp binding is not directly
related to subcellular distribution of these proteins (Zerrahn
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Perhaps the formation of complexes does not

et al., 1992).

govern the location and related activity of p53, but rather
p53

location

is

simply

dependent

on

its

conformational

phenotype.
In another study, researchers examined how mutant p53
proteins overcome growth regulation by the wild-type p53
allele and protein in a cell (Martinez et al., 1991).

The

exact mechanism by which the temperature-sensitive mutant
p53val135 was detected was espoused.

The conformational

change of the p53val135 was detected by the binding of PAb246,
which bound the wild-type or majority of p53val135 at 32.5°C,
but did not recognize the mutant form at 39.5°C.

At 39.5°C,

the mutant p53 was localized in the cytoplasm, while at 32.5°C
it

entered

the

nucleus.

At

32.5°C,

the

cells

stopped

replication and remained at the Gl/S border, accumulating in
the Gl phase.
type p53,

At 37°C there was a mixture of mutant and wild

forming a complex with the cellular heat shock

protein hsp70 in the cytoplasm of the cell during Gl phase.
This

experiment

suggests

that

mutant

p53

proteins

in

transformed cells may sequester wild-type p53 protein in an
hsp70-p53 complex in the cytopla'sm during the Gl phase of the
cell cycle (Martinez et al., 1991).

In this way, wild-type

p53 is kept from its normal nuclear location and hence its
function of tumor suppression is adversely affected.

The

"dominant negative" mechanism by which mutant p53 subverts the
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suppressive activity of wild-type p53 has thus been partially
substantiated, with many details yet to be explained.

It has

also been postulated that perhaps hsp70 normally binds to the
wild-type protein

alone;

the

hsp70

may

keep

it

in

the

cytoplasm until its function is required, upon which it is
unbound and enters the nucleus.

If this scenario is correct,

then the location and activity of p53 may be more dependent on
the formation of complexes than the conformational phenotype
as suggested by Zerrahn et al. (1992).
Another characteristic of p53 studied in further detail
was the exact location within the cell cycle where wild-type
p53 growth arrest occurs. The cell cycle is divided into four
stages, including: Gl, s, G2, and M.

During Gl and G2 (gap)

stages, very little is going on in the cell.

There are two

restriction points,

that help to

or decision checkpoints,

determine the fate of the cell.

One occurs at the Gl/S

(synthesis) interphase, where the decision for the cell to
undergoe DNA replication is made.

The other is at the G2/M

(mitosis) interphase, where the decision for cell division
into two daugther cells is made.

Lin et al. (1992) showed

that growth arrest induced by expression of wild-type p53
protein in a GBM cell line occurred prior to or near the
restriction point in late Gl phase of the cell cycle. The GBM
cell line used was T98G (the parental human line), along with
sublines GM47.23 (a stable transfectant of T98G) and Mdel 4A.
These contained a dexamethasone (DEX) inducible wild-type p53
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protein which could be used to define the position in the cell
cycle

where

growth suppression

by wild-type

p53

protein

occurred (Mercer et al., 1990 and 1991). Also examined within
the growth arrest stage of GBM cells was the phosphorylation
and conformational state of wild-type p53

(Ullrich et al.,

As indicated in this study, the amount of wild-type

1992).

p53 associated with the mutant fraction decreased as Gl arrest
was

entered.

phosphorylated

Free

wild-type p53

than

mutant

p53

was shown
by

to

be

two-dimensional

more
gel

analysis. This experiment proposes that phosphorylation leads
to a different conformational mechanism by which wild-type p53
acts

differently

from

mutant

p53

to

induce

antiproliferative effect (Ullrich et al., 1992).

an

Figure 2

shows the effects of normal p53 and mutant p53 on the growth
arrest stage of the cell cycle.

Gradually the effects of p53

on cells have been revealed, but there are still many areas
which

warrant

consideration.

As

aspects

such

as

p53

localization in the cell and site of cell cycle arrest were
being explored,

a major focus began on the specific DNA

binding function of p53 and the expression of its genes.
It is already known that p53 is altered in a number of
different

cancers

by

a

missense

mutation.

To

better

characterize the effects of these mutations, wild-type p53
protein was shown to bind to a specific human DNA sequence in
vitro (Kern et al., 1991}.
binding

site,

cloned

DNA

To identify a sequence-specific
sequences

were

screened

by
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immunoprecipitation techniques.
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By immunoprecipitation with

mAb's against p53 (anti-p53), labelled DNA fragments bound to
p53 were recovered.

As few as 33 base pairs were needed for

specific binding, and certain guanines within this 33-base
pair region were essential,
inhibit binding.

for a mutation of them could

Human p53 proteins with missense mutations

could not bind to this sequence.

In this way, mutations such

as those in tumor DNA could affect the necessary binding
affinity of p53 for specific DNA sequences

(Kern et al.,

1991).
Funk et al. (1992) initially identified transcriptionally
active

DNA-binding

complexes.

sites

for human

p53

protein

and

its

It was suggested that P53 formed complexes with

DNA directly or along with other proteins.

The p53 tumor

suppressor protein has transcriptional activation regions in
addition to specific DNA-binding sites for p53. Based on this
information, it is apparent that the p53 protein functions as
a transcription factor.
isolated

was

The specific DNA-binding sequence

GGACATGCCCGGGCATGTCC,

which

promoted

p53-

dependent transcription when placed upstream of a reporter
gene (Funk et al., 1992).

At this point, the complementary

DNA-binding elements for p53 could then be determined.
A subsequent study by Zambetti et al. (1992) identified
the first example of a naturally occurring wild-type p53specific DNA-binding element that is able to mediate positive
expression of a test gene.

A 50-bp region was identified as
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the p53 protein/DNA-binding element, for the 50-bp sequence

induced wild-type p53 responsiveness on an enhancer-promoter
region

of

the

test gene

( Zambetti et al.,

1992).

The

importance of this experiment was to propose a method of gene
regulation by the DNA-binding ability of wild-type p53 protein
that is absent in the mutant p53 proteins.
Another DNA-binding element for the wild-type p53 protein
was the murine double minute-2 (mdm-2) gene, frequently found
to be amplified in human sarcomas and localized to the altered
chromosome 12q13-14 (Oliner et al., 1992). In these sarcomas,
the human mdm-2 gene was cloned as a gene encoding a p53associated protein.

Its exact role in the association with

p53 was unknown, although it was suggested that it served to
functionally inactivate wild-type p53.

In this experiment,

human mdm-2 protein was-shown to ·bind to the protein encoded
by the human p53 gene in vitro.

MDM-2 binds to p53 and upon

amplification, it can lead to escape from p53-regulated growth
control (Oliner et al., 1992).

Further work with mdm-2 was

done in which it was classified as a p90 oncogene and multiple
mdm-2 proteins and mdm-2-p53 protein complexes were identified
(Olson et al., 1993). The mdm-2 p90 protein and at least four
other polypeptides were detected (p85, p76, p74, p58-57).

Of

these, the p90 and p58 proteins were found to form complexes
with the p53 protein.

It is suggested that the p90 mdm-2

protein regulates p53 activity in the critical late Gl phase
of the cell cycle (Olson et al., 1993).

Therefore, mdm-2 is

3"6
involved in a negative feedback loop, for the p53 DNA binding
site is upstream of mdm-2,
expression.

enabling it to

induce mdm-2

An overexpression of mdm-2 would cause the p53

gene to stop transcription of this downstream effector gene.
Also,

if

the

mdm-2

protein

is

capable

of

functionally

inactivating the p53 tumor suppressor gene, this could be an
alternative to direct mutations of the p53 gene thought to be
essential in many cancers.

As noted in gliomas, there is a

lower frequency of mutation rate, so alternatives to direct
mutations of p53 are rapidly being introduced.

In gliomas in

particular, there is a low incidence of mdm-2 overexpression.
At this point, the question of stimulation of p53-DNA binding
and

the

mechanism

of

consequent

tumor

suppression

was

addressed.
An important study by Price and Calderwood (1993) showed
an increase in p53-DNA binding activity after DNA damage.

An

increase in the level of tumor-suppressor gene p53 is the
result of a "signal" that there is DNA damage, and therefore
the

cell

cycle

can be arrested in

replication of the aberrant DNA.

Gl

phase

to

prevent

This "signal" is the

critical binding of wild-type p5J to specific DNA sequences,
which incidentally increases the half-life of the p53 protein.
However,

if there is an interruption in the cellular p53

response to DNA damage, binding activity and the half-life of
the p53 protein will decrease,

and potentially there is

replication of damaged DNA and consequently tumor promotion.
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So, this experiment by Price and Calderwood (1993) proved the
importance of DNA binding activity to p53 tumor suppressor
function in the cell.

Another innovative participant in the mechanism of p53
tumor suppression appears to be the recently discovered WAFl
gene, or wild-type p53-activated fragment 1 (El-Deiry et al.,
1993). It is essential to note that a simultaneous experiment
localized the same product as the p21 CDK (cyclin-dependent
kinase)- interacting protein, or Cipl (Harper et al., 1993).
P53 specifically activates transcription of WAFl, but only wt
p53 is capable of inducing WAFl.

In the experiment, WAFl was

localized to chromosome 6p21.2, and a p53-binding site was
identified 2.4 kb upstream of WAFl coding sequences.

WAFl

product proves capable of suppressing the growth of human
A subsequent

brain, lung, and colon tumor cells in culture.

experiment by the same team of researchers found the mechanism
of WAFl action to be effective at the stages of p53-mediated
Gl arrest and apoptosis, or programmed cell death.

Induction

of WAFl/CIPl protein took place by exposure to DNA damaging
agents in wild-type p53-associated cells undergoing Gl arrest
or

apoptosis.

Induction

did, not

occur

in

mutant

p53-

containing cells or cells undergoing these processes through
p53-independent mechanisms (El-Deiry, 1994).

It had become

clear that WAFl/CIPl, induced by p53, functions to inhibit
cyclin-dependent

kinases

(CDK's).

It

is

these

cyclin

dependent kinases that allow the cell cycle to proceed through

the Gl phase in normal cell cycle progression.

So,
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the

mechanism for p53's regulation of cell proliferation relies on
its transcription of the WAFl gene that can inhibit the CDK's,
thereby preventing a progression of the cell cycle beyond an
arrest at the Gl stage.

Figure 3 shows the interaction of p53

with its transcription-dependent genes mdm-2 and WAFl.
this way,

In

the mechanism of p53 function is being pieced

together, and WAFl represents an area of interest, for if this
downstream effector is altered in some way, it affects the
funtional activity of p53.

This can occur by mechanims

independent of p53 mutations, and could account for another
reason why the p53 mutation rate is low in gliomas.
Cell cycle arrest and DNA-binding activity are two of the
many advances in the characterization of the p53 gene that
enable it to be better applied in the treatment of gliomas and
other cancers.

Another area of interest includes the role of

p53 in familial disposition to certain types of cancer, as the
potential

for

more

effective diagnosis

and

prognosis

is

explored.
Familial Cancer syndromes
Carcinogenesis is a very complex process, involving both
environmental and host factors that can influence a person's
susceptibility to cancer.

It is important to note that with

gliomas, there is no known environmental situation that can

39

DNA

&wi Damage
•

(-)
11&\
�
� / ( +)
""

( +)

/

p53

,

\

�

mdrn-2

M

Alil'\
l(f!V

G2

CDK I s

e
Figure 3.

Gl
s

Cell cycle
at restriction point
of Gl phase before
replication of altered
DNA.

Incorporation of mdm-2 and WAFl into the
p53 Tumor Suppressor Model
+

stimulate
inhibit

cause

or

neoplasia.

facilitate

the

development

of

primary

40
brain

In the case of lung cancer, smoking is the leading

cause, and with skin cancer, exposure to the sun represents a
major etiology for tumorigenesis.

Despite the different

methods of acquisition, however, there is a common bond, for
many of these cancers are inherited disorders that can be
detected early.

In common with the Rb gene in the inheritable

disease retinoblastoma, p53 germ line mutations appear to be
a unique indicator of many types of cancers associated with
familial disorders.
One of the primary disorders that has been studied in
relation to p53 mutations has been the Li-Fraumeni syndrome
(LFS), a rare autosomal dominant condition characterized by
various epithelial and mesenchymal neoplasms at diverse sites
(Srivastava et al., 1990).
and

Fraumeni

reviewed

originally proposed in 1969, Li

the

medical

r,ecords

and

death

certificates of 648 childhood rhabdomyosarcoma patients and
identified four families in which siblings or cousins had a
childhood sarcoma,

along with family histories of. breast

cancer and other neoplasms (Malkin et al., 1990). The cancers
specifically identified in this syndrome included:

breast

carcinomas, soft tissue sarcomas, brain tumors, osteosarcoma,
leukemia,

and

adrenocortical

carcinoma.

Other

possible

component tumors of LFS included: melanoma� gonadal germ cell
tumors, and carcinomas of the lung, pancreas, and prostate.
In this way, a definition of what constituted the Li-Fraumeni
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syndrome was constructed (Li and Fraumeni, 1969; Malkin et
al.,

1990;

Srivastava

et

al.,

1990).

Eventually,

p53

mutations were used as valuable indicators of this inheritable
disease.
A recent study involved the analysis of the entire coding
sequence of the p53 gene for the presence of mutations in
twenty-one

Li-Fraumeni

families

(Birch

et

al.,

1994).

Mutations were detected in seven of these families, including:
six point mutations affecting codons 175, 180, and 220, three
affecting codon 248, and one was a deletion/insertion mutation
in exon 4.

These seven mutations were analyzed along with

thirty-four published examples, and the most common cancers
occurring

in

the

forty-one

families

with

germline

p53

These

mutations and classic LFS characteristics were noted.

included: bone and soft tissue sarcoma, breast cancer, brain
tumors, leukemia, and adrenocortical carcinoma (Birch et al.,
1994).

Through experiments such as this, it is apparent that

germline p53 mutations can potentially serve to identify
asymptomatic carriers of these various cancers. However, this
presents

an ethical question as to what extent the p53

mutations can be used to identify these carriers, for the
relevance

of

these

traits

could

have

serious

social

ramifications.
Another familial cancer syndrome associated with p53 gene
mutations

along

Recklinghausen

with

chromosome

neurofibromatosis

17

deletions

(NFl).

The

is

van

clinical
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manifestations of this disease include: mental retardation,
learning disabilities, macrocephaly, and bone abnormalities.
Characteristic of NFl is the formation of neurofibromas, which
usually

occur

in

the

skin

but

may

also

involve

deeper

peripheral nerves and nerve roots as well as viscera and blood
vessels innervated by the autonomic nervous system (Riccardi,
1981).

The

neurofibromas

are

benign

histologically

but

malignant transformation progresses to neurofibrosarcomas,
which are ultimately lethal (Sorensen et al., 1986).

A study

by Menon et al. (1990) attempted to better classify the genes
involved in this particular hereditary disorder.

By direct

sequencing of PCR-amplified DNA from seven neurofibrosarcomas,
it was found that two contained point mutations in exon 4 of
the p53 gene. This indicated·that several genetic events were
responsible for the tumorigenesis of NFl, and that for some
neurofibrosarcomas inactivation of p53 appeared to be one of
them.

Table 2 summarizes some of the tumor suppressor genes

associated with familial cancer syndromes.
Despite the low p53 mutation rate in gliomas as compared
to that in other cancers,

the p53 gene can be used as a

valuable indicator of the cancers associated with several
familial diseases.

And, while many of the mechanisms behind

the involvement of p53 are unclear, its consistency in some of
these cancers points to the usage of p53 in experimental
procedures such as gene therapy.
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Table 2.

Summary of Tumor Suppressor Genes Associated with
Familial Cancer syndromes

Tumor Suppressor
Gene

Familial Cancer
Syndrome

Cellular
Location/
Function

Major
Mutation

Rb

Retinoblastoma

nucleus/
transcription
modifier

deletion
nonsense

p53

Li-Fraumeni

nucleus/
transcription
factor

missense

cytoplasm/
GTP
activating
protein

deletion

NFl

Von Recklinghausen
Neurofibromatosis
(Neurofibromatosis
type 1)
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Gene Therapy
Gene therapy is a relatively new technique involving the
treatment of disease by the introduction of healthy genes.into
the body (Verma, 1990). A likely candidate for this procedure
is the p53 tumor suppressor gene, for if a wild-type p53 gene
can be reintroduced, it may restore tumor suppressor function.
When the wild-type p53 gene is initially inactivated,

it

usually involves a mutation of the normal gene product into a
mutant one.

Also, other regulator genes of the p53 gene such

as mdm-2 and WAFl are adversely affected if the p53 gene is
altered in some way. Therefore, if a normal wild-type gene is
transfected into a cell that has undergone p53 mutations, then
the normal p53 gene should theoretically be able to restore
tumor suppressor function.
Based on this hypothesis, Mercer et al. (1990) attempted
to conditionally express human wild-type p53 and display its
ability to negatively regulate cell growth in vitro.

They

constructed a recombinant plasmid, pM47, in which wild-type
p53 cDNA was under transcriptional control. The pM47 was then
introduced into the human GBM tumor cell line T98G.

A stable

clonal cell line, GM47.23, was developed that conditionally
expressed wild-type p53 upon induction by dexamethasone.
Results showed that induction of wild-type p53 expression by
dexamethasone

resulted

in

inhibition

of

cell

cycle

progression.

The effect was reversible upon removal of
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dexamethasone, resulting in a return to the mutant function of
tumor promotion.

More specifically, inducible wild-type p53

was capable of inhibiting Gl progression into S phase.
experiment

showed

that

wild-type

p53

could

indeed

This
be

transfected into a cell displaying a mutant characteristic,
and

could

reenact

the wild-type p53

incorporation (Mercer et al., 1990).

gene

function

upon

This proved to be a

novel step supporting gene therapy, but the problem of gene
delivery remained an issue to be further explored.
stable transfectants needed to be developed,

More

for although

wild-type p53 proved effective in vitro, the conditions under
which it would work in vivo would be quite different.
There are several methods of gene delivery that have been
developed over the past couple of years.

One such technique

involves retroviruses, which are small (10 kb) RNA viruses
with a single-stranded RNA genome that is converted to DNA by
reverse transcriptase carried in the virus particle (Morsy et
al.,

1993).

Another mode of gene delivery includes the

adenoviruses such as ElA,
stranded DNA viruses.

which are large

( 38kb) double

As opposed to these viral vectors, a

recombinant construct can be used for chemical and physical
delivery systems, in which a recombinant DNA molecule with a
promoter and a polyadenylation signal is incorporated into a
DNA backbone.

After the most efficient methods of gene

delivery have been demonstrated, the most effective gene for
delivery must be defined.
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P53 represents a unique addition to the concept of gene
therapy.

Gene therapy could prove to be a very effective

means of treatment in cancers in which the p53 mutation rate
is high, such as colorectal and lung.

However, in cancers

such as gliomas where the p53 mutation rate is low,

the

prospect of p53 in successful gene therapy may not be as
applicable.

Still, if even a small percentage of gliomas are

positively affected by p53 gene therapy, then an innovative
treatment has been introduced.
and

its

associated

genes

in

Also, the exact role of p53
gliomas

should

be

further

elucidated so that techniques such as p53 gene therapy can be
more effective.

Role of p53 in Gliomas
As more becomes known about the traits of the p53 tumor
suppressor gene,

the closer this molecule comes to having

practical applications in a clinical sense.

Specifically,

initial studies of the mutations of the p53 gene reveal that
it can be used as a diagnostic indicator of the malignancy
grade of gliomas (Sidransky et al., 1992; Fults et al., 1992).
At this time, it is essential to distinguish two lines of
thought concerning mutations of the p53

gene.

One idea

supports the fact that mutations of the p53 gene in gliomas
can be used for clinical applications.

The other position

maintains that the frequency rate of p53 mutations in gliomas
is too low to be a useful indicator for this type of cancer.
Perhaps a common theme between these two proposals is the
progressively

different

molecular

determine p53 gene mutations.

techniques

employed

to

The rationale behind both of

these theories will be discussed in relation to one another.
Correlation With Tumor Grade
A decisive study of p53 mutant cells sought to determine
their associations with brain tumor progression by cloning
techniques (Sidransky et al., 1992). Based on the observation
47
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that low-grade astrocytomas evolve into faster-growing, more

invasive high-grade tumors (i.e. GBM), Sidransky et al. (1992)
investigated the genetic basis for this progression. They
found that out of four recurrent tumors studied, three of them
had the same p53 mutation associated with the primary tumor.
Also, progression to high-grade tumors was associated with the
p53 gene mutation as well. They concluded brain tumors occur
by the clonal expansion of cells that had previously acquired
a mutation in the p53

gene,

selective growth advantage

which provides them with a

(Sidransky et al.,

1992).

The

basis of this experiment was Nowell's (1976) clonal evolution
model of tumor progression. This proposed that most neoplasms
arose from a single cell of origin and tumor progression
sequentially resulted from acquired genetic lesions within the
original clone

(Nowell, 1976).

This model of tumor cell

genetic instability would help associate p53 mutations with
malignancy grade, for the more aggressively developing tumor
sublines would be the more malignant ones.
The link between p53 mutation and loss of heterozygosity
on

chromosomes

astrocytoma

17

and

10

was

uniquely

progression

by

Fults

et

al.

connected
(1992),

with

having

originally been introduced in brain and other cancers by Nigro
et al. (1989).

The results of a sequence analysis of the p53

tumor suppressor gene and an RFLP analysis of chromosomes 17
and 10 were correlated in forty-five patients with cerebral
astrocytomas

at

different

stages.

Single-strand
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conformational polymorphism (SSCP) analysis of PCR products
was done to detect p53 mutations in tumor DNA,

and these

mutations were confirmed by sequencing (Fults et al, 1992).
Southern transfer analysis of somatic and tumor DNA using
polymorphic

markers

was

used

to

determine

loss

of

heterozygosity. The results showed that p53 mutations were
found in twenty-eight percent of GBM, thirty-six percent of
AA, and none of the low-grade astrocytomas.

Also, sixty-two

percent ·of patients with loss of heterozygosity on chromosome
17p had p53 mutations.

P53 could be important in astrocytoma

progression, for its inactivation could trigger a malignant
transformation.
In a related study, twenty-two human astrocytomas of WHO
grades II and III were studied for corresponding mutations of
the p53 gene and loss of heterozygosity on chromosome 17p (Von
Deimling et al., 1992).
gene

(exons

5-8),

In the conserved regions of the p53

SSCP

analysis

was

used

to

identify

mutations, and direct DNA sequencing of PCR products was used
to verify them.
grade

II

P53 mutations were found in three of eight

astrocytomas

and

four

of

fourteen

grade

III

astrocytomas, and these mutations were found exclusively in
tumors with allelic loss on chromosome 17p. - Because of the
association of these p53 mutations with loss of heterozygosity
of chromosome 17p in lower-grade astrocytomas,

p53 - may be

important in the progression of low-grade tumors and not just
present in the high-grade ones.
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In

one

study

comparing

p53

mutations

to

loss

of

heterozygosity on chromosome 17p in high-grade gliomas (WHO
grades III and IV), there were p53 mutations in 64% of the
tumors with one 17p allele (Frankel et al.,

1992).

In the

gliomas that retained both 17p alleles, the frequency rate of
p53

mutations

was

only

thirty-seven

percent.

overall,

mutations of the p53 gene occurred in forty percent of the
gliomas, whereas these values were much higher in cancers of
the lung and liver,

greater than fifty and eighty percent

respectively.
Because of the advent of new technologies, p53 mutations
in gliomas have been studied throughout the various malignancy
stages.

For instance, antibodies were used in conjunction

with one another to provide more effective screening of p53
protein expression in central nervous system tumors.

Tumors

were immunostained with the CMl polyclonal antibody (pAb) and
the D0-7 rnAb against the p53 protein (Karamitopoulo et al.,
1993). This immunostaining with CMl pAb and D0-7 rnAb was used
to test for abnormal p53 expression at different stages of
malignancy

(Haapasalo et

al.,

1993).

The

staining

was

positive in forty-nine percent 0£ malignant neoplasms (grades
III and IV), and in nineteen to twenty-nine percent of grade
II

astrocytomas,

positive.
proliferation

P53

while none of the grade
expression

rate,

as

was

closely

determined

by

I tumors

were

correlated

with

immunohistochemical

staining of the proliferating cell nuclear antigen (PCNA).
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Proliferation rates were higher in mutant p53 tumors because
the PCNA only binds to mutant p53, as the wild-type p53 downregulates PCNA (Mercer, 1991).
similar

tumors

could

be

In this way, histologically

separated

into

prognostically

different subgroups based on levels of altered p53 ·expression
(Haapasalo et al., 1993).

By measuring the amount of mutant

p53 expression, it appears that it correlates with degrees of
malignancy.

The more malignant forms of gliomas seem to have

more mutant p53 expressed, perhaps due to increased half-life
and degree of phosphorylation.

This correlation can be quite

valuable clinically, for the amount of aberrant p53 expression
can tell how far a tumor has progressed, and perhaps what
treatments would be most effective at that juncture.
the levels of p53 mutation in gliomas are low,

Still,

and that

questions the extent to which this method of diagnosis can be
effectively used.
Inconsistencies in Mutation Rate
Throughout the many studies of p53 mutations in gliomas
using various molecular techniques,
useful

results,

but

a

problem

has

there have been many
persisted.

Despite

accumulation of P53 protein, the observed frequency of p53
mutations in gliomas is lower than that of other cancers such
as colorectal, lung, and breast.

Two possibilities for the

discrepancy have been suggested.

First, the role of p53 as a
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universal tumor suppressor gene may not be true for gliomas.

Alternatively, malignant progression in gliomas may proceed by
various means of functionally inactivating wild-type p53 that
do not involve direct p53 mutations, making the glioma quite
A number of reports have examined the low frequency

elusive.

of p53 mutations in various grades of gliomas.
In a study by James et al.

(1988),

glioma malignancy

stages were examined by restriction fragment length alleles to
determine the genomic position of various recessive mutations.
It

was

shown

that

the

major

alteration

was

a

loss

of

constitutional heterozygosity for loci on chromosome 10 in
twenty-eight
chromosome

of

10

twenty-nine

was

the

GBM.

essential

progression from grade III

This
chromosome

(AA) to grade IV

displayed
lost

in

(GBM).

how
the
To a

lesser extent, restriction.fragment length alleles showed that
sequences on chromosomes 13,
nonrandom frequencies.
chromosome

17,

17, and 22 had been lost at

It did not appear that loss of

and therefore the mapped p53 gene,

was

critical to glial tumor progression.
Compared to the allelotype discussed earlier on human
colorectal carcinoma (Vogelstein et al., 1989), it appeared
that there were two different methods of allele loss by each
type of cancer.

Perhaps the tumorigenesis of colorectal

carcinoma and malignant astrocytoma were taking place by two
different genetic pathways, with colorectal cancers dependent
on p53 mutations and gliomas dependent on ·loss of chromosome

53

10. This would explain the observation that p53 mutation rate

frequency is significantly higher in colorectal carcinomas as
Again, much of this speculation is based

opposed to gliomas.

on the current molecular techniques used at the time,

and

these have advanced along with the study of cancer.
P53

gene mutations in human brain tumors have been

studied by a variety of increasingly accurate techniques.
Single-strand

conformation

polymorphism

analysis

of

PCR

products (PCR-SSCP) is a very effective method of detecting
mutations of the p53 gene in human brain tumors (Mashiyama et
al., 1991).

Out of forty-five brain tumors analyzed, six of

them showed mobility shifts and loss of a normal allele.
Using direct sequencing of the six mutations,

five were

clustered

p53

in

highly

conserved

regions

of

the

gene.

Excluding these six mutations however, the frequency rate of
p53 gene mutations in primary brain tumors in this experiment
was only 9.8 percent.

Despite the advancing technology of

detecting mutations in the p53 gene, it did not appear that
these were correlated with the malignancy of brain tumors in
this case.
A

subsequent

study

using

monoclonal

antibodies

and

immunocytochemistry detected a higher rate of p53 mutations in
human gliomas (Bruner et al., 1991).

Because the wild-type

p53 protein has a short half-life and is not detectable by
this method, only the mutated p53 protein could be analyzed.
Antibody staining for p53 protein was found in twenty-nine of

seventy-one

(41%)

brain biopsies.
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These values are still

relatively low overall, and together with consistent evidence,
it indicates that p53 may not be a universal indicator of
malignancy grades of gliomas.
Another experiment by Van Meir et al.
specifically
biological

determine

whether

function was

progression.

loss

(1994) sought to

of

wild-type

a necessary step

astrocytoma

Thirteen glioma cell lines displayed various

amounts of p53 protein by immunoprecipitation.
were

in

p53

transfected

with

a

plasmid

construct

The cell lines
containing

chloramphenicol acetyltransferase (CAT) reporter gene.

a

The

CAT was under the control of transcriptional elements that are
induced by wild-type but not mutant p53.

In this way, the

expression of wild-type p53 could be detected. Four lines were
shown to retain wild-type p53 function.

In two of these cell

lines, the wild-type p53 genotype was accompanied by a mutant
phenotype

with

development.

either

the

presence

or

absence

of

tumor

With the inhibition of tumor development, it was

evident that the wild-type p53 allele was still exerting its
effect.

However, with the stimulation of tumor development,

apparently the mutant p53 allele inactivated the remaining
wild-type p53 allele by the "dominant negative" effect.

The

observation that two cell lines conveyed a wild-type genotype
indicated that inactivation of the p53 gene by mutation was
not

required

for

GBM

genesis.

This

suggests

that · the

formation of a GBM may take place by two pathways; one that is

p53 mutation-dependent and the other not.

Therefore,
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p53

mutations are not necessarily the primary reason for glial
tumorigenesis; rather,
alternate pathways.

p53 inactivation may take place by

Table 3 summarizes the various wild-type

and mutant p53 genotype and phenotype combinations and their
cellular responses.
An increasingly significant trend

that has

appeared

recently in gliomas is the elevated levels of wild-type p53
protein without p53 mutations.

In an experiment by Rubio et

al. (1993}, SSCP analysis and DNA sequencing were used to show
absence of p53 mutations despite accumulating levels of wild
type p53, detected by immunohistochemistry.

This observation

presents a novel situation in the case of gliomas.

In other

cancers such as colon and lung, mutations of the p53 gene are
prominent.

These mutations are predicted to be the primary

genetic lesion in these forms of carcinomas.
case

of

gliomas,

mutations

are

not

the

However, in the
primary

genetic

aberration, for there is accumulation of wild-type p53 without
mutation.

Therefore,

there must be other mechanisms that

cause the tumorigenesis of gliomas.
of

an

mdm-2

product

to

For example, the binding

p53 ,could

inactivates the p53 protein.

form

a

complex

that

However, in this experiment,

mdm-2 gene amplification was not observed.

For this reason,

other participants must be examined and further testing must
be

done.

Recent studies emphasize the results

experiment by Rubio et al. (1993}.

0£

this
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Table 3.

Possible p53 Genotype and Phenotype Combinations
and Subsequent Cellular Responses

p53 Genotype

p53 Phenotype

Cellular Response

1.
wild-type

wild-type

normal (no tumor
development)

wild-type
p53 tumor
suppression

2.
wild-type

mutant

normal (no tumor
development)

wild-type
p53
overcomes
mutant p53
effects

3.
wild-type

mutant

tumor
development

Hypothesis

mutant p53
inactivates
wild-type
p53
(Dominant
Negative
Effect)
or

in gliomas:
inactivation of p53
takes place by
alternative factors
such as mdm-2 or
WAFl that can
circumvent direct
p53 mutations
4.
mutant

mutant

tumor
development

complete
inactivation
of wild-type
p53 tumor
suppression
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A current report also supports the finding that p53
mutations are low in gliomas despite accumulation of wild-type
p53.

Lang et al.

(1994) found wild-type p53 protein without

p53 gene mutation in thirty-one non-GBM gliomas (WHO grades I
III). Immunohistochemistry detected p53 protein accumulation
in

seventy-one

astrocytomas

percent

(WHO

astrocytomas

grade

of

human

I),

(WHO grade II),

juvenile

sixty-three

pilocytic

percent

of

and sixty-three percent of

anaplastic astrocytomas (WHO grade III).

P53 mutations were

detected in fourteen percent of grade I, twenty-five percent
of grade II, and nineteen percent of grade III astrocytomas.
A total of fourteen tumors, sixty to eighty percent within
each grade, showed p53 protein accumulation without detectable
mutations of the p53 gene (Lang et al., 1994).

Incidentally,

no correlation between grade of astrocytoma and percentage of
immunostained
diminishing
indicator

cells was observed,

prevalence
of

further

of p53 aberrant

malignancy

grade.

expression

Also,

amplification was seen in these tumors.

indicating
no

mdm-2

the

as

an

gene

The results of this

experiment indicated that p53 gene inactivation by mutation or
mdm-2 complex formation was appaFently not essential for glial
tumorigenesis.

Therefore, there must be mechanisms of glial

tumorigenesis that circumvent direct p53 mutations.
Current estimates using loss of heterozygosity analysis
with RFLP markers indicate that only forty percent of low- and
intermediate-grade tumors and thirty percent of high-grade
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tumors contain allelic deletions on chromosome 17p (Leon et
al., 1994). The finding of loss of heterozygosity for alleles
on 17p without detectable p53 mutations in some tumors further
suggests alternatives to the direct genetic p53 involvement
both in gliomas and other cancers.

There may be a second

tumor suppressor gene on chromosome 17p that is also affected
in the progression to malignancy of some gliomas (Frankel et
al.,

1992).

(Fults

Perhaps other chromosomes such as 9p and 10

et al.,

suppressor

1990) are involved with their own

genes,

in

addition

amplification of the EGFR gene.

to

the

effect

of

tumor
the

P53 pathways may be bypassed

due to the mutations in downstream effector genes (Van Meir et
al.,

1994).

This statement alludes to the work already

discussed involving the mdm-2 negative regulator of p53 in
sarcomas (Oliner et al., 1992; Olson et al., 1993).

In this

case, mdm-2 would bind to p53 in a .complex that would not
allow p53 to function properly.

In the same way, the heat

shock protein 70 (HSP-70) is also believed to be capable of
binding to p53 in a complex that inactivates it, primarily by
removing p53 from its nuclear location of function.
the WAFl DNA sequence is mutat:ed,

Also, if

then the wild-type p53

protein cannot bind and initiate transcription of the WAFl
protein, which would inhibit CDK's and therefore cell cycle
progression.

It is also possible that alternatives to p53

mutation may be primarily involved when applied to certain
grades of gliomas but not all of them.

These mechanisms that
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may be responsible for affecting the function of the p53 tumor
suppressor gene in gliomas must be discussed further.
Alternatives Circumvent Direct p53 Mutations
In order to better understand the mechanisms by which the
p53 gene suppresses tumor growth, it is necessary to examine
other co-participants in this process.
Rubio et al.

As demonstrated by

(1993), Lang et al. (1994), and Van Meir et al.

(1994), gliomas apparently have high accumulations of wild
type p53 in addition to lack of p53 mutations.
indicate

that

p53

protein

tumorigenesis process,

is

important

These figures
in

the

but that other candidates

direct p53 mutations may play a supportive role.

glial
besides
Several

experiments have been done to examine these indirect methods
in closer detail, both in other cancers and gliomas.
The binding of p53 with other cellular proteins is
becoming an area of focus in an attempt to understand the
mechanism of p53 tumor suppression.
proteins

are

Perhaps these cellular

required in some manner to allow for

mechanism to work properly.

this

It,has been shown that cellular

proteins bind to a specific conformational domain of the p53
protein

(Maxwell and Roth, 1993).

In immunoprecipitation

assays performed for lung-cancer lines, proteins of molecular
weights 45K, 56K, and 70K in addition to others ranging from
30K to 90K were found to be in association with the wild-type
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p53 protein. Proteins such as these might be required to bind
to the p53 protein in a complex that directs correct p53-DNA
binding.

As Maxwell and Roth (1993) noted, binding of the

SV40 large T-antigen protein (Lane and Crawford, 1979) to a
conserved, conformational domain of p53 inhibits p53's DNA
binding and consequent transcription activation activities.
It is a logical conclusion that cellular proteins such as this
one could also associate with various regions of the p53 gene
and similarly down-regulate the action of the p53 gene.
DNA

tumor

also

exhibit

examples

of

wt-p53

One method of p53 inactivation involves the

inactivation.
association

viruses

of

human

papillomavirus types

16

and

18

E6

proteins with p53, originally shown by Werness et al. (1990).
Human papillomavirus type 16 (HPV-16) encodes two transforming
proteins,

E6 and E7.

The E7 protein binds to the Rb gene

product, while the E6 protein has been shown here to bind to
the cellular p53 protein.

The significance of the ability of

HPV-16 and -18 E6 proteins to form complexes with the p53
protein was further clarified.

It was shown that the E6

oncoprotein

the

actually

promotes

(Scheffner et al., 1990).

degradation

of

p53

The results showed that less p53

was present after incubation with HPV-18 E6, and no difference
after incubation with HPV-11 E6, which does not bind to p53.
Dominant-acting oncoproteins such as E6 could prove to be a
vital

participant

in

the

inactivation

of

p53

function.

Building upon the work of Werness et al. (1990) and Scheffner
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et al. (1990}, HPV-16 E7 and adenovirus ElA oncoproteins were
shown to overcome the growth arrest of cells induced by
temperature-sensitive

p53

(Vousden

et

al.,

1993).

Proliferation of rat embryo fibroblasts was shown to cease
after the cells were exposed to a temperature-sensitive p53
mutant at 33°C.

Subsequently, this growth arrest was overcome

by the expression of oncoproteins HPV-16 E7 and adenovirus
ElA. Also, there were no detectable changes in p53 expression
or

conformation

in

these

cells

involved,

showing

that

inactivation of p53 tumor suppressor function occurred without
direct effects on p53.

Overall, this experiment displays a

plausible alternative to mutations affecting p53 function, for
E'7

and ElA oncoproteins appear to suppress wild-type p53

growth-suppressor

activity

without

affecting

the

protein

This is different from the original coordinated

itself.

proposa.l that p53 mutations were necessary for inactivation of.
function.
Another

possible method of indirect tumor formation

without p53 mutation is the presence of two oncogenes.

It has

been shown that activated oncogenes ras and myc together can
cause carcinoma development without p53 mutation (Lu et al.,
1992).

No mutations were observed in ras and myc-transformed

mouse prostate carcinoma cells,

and their growth was not

inhibited when transfected with wild-type human p53 plasmids.
In this scenario, it appears that carcinogenesis is occurring
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independent of p53 mutation. Still, it does not mean that p53

is not involved in some way, for perhaps the two oncogenes
somehow force p53 from its location of function in the cell.
This has not been proven, but it is possible that p53 is
involved despite the apparent lack of p53 mutations.
An

example

for

cellular

alternatives

to

frank

p53

mutation is the mdm-2 gene, which has been shown to have
negative effects on p53 function in sarcomas.

It has also

been shown in a recent study that eight to ten percent of 157
GBM and AA showed mdm-2
(Reifenberger

et

al.,

relatively small,

amplification and overexpression

1993).

This

percentage,

although

could account for at least some of the

remaining percentage that has been left unexplained by the low
p 5 3

m u t a t i o n

r a t e

i n

g 1 i o m a s .

The results of this study showed that mdm-2 amplification was
present in six of seventy-five GBM and three of twenty-seven
AA

(Reifenberger et al.,

1993}.

Although these results

suggest that mdm-2 plays a very minor role in GBM, they open
the possibility of as yet unidentified cellular products which
could negatively modulate wild-type p53.
In the p53 tumor suppressor model, it is difficult to
consider co-factors such as mdm-2 and WAFl as completely
independent of p53, for they too are subject to alteration.
Upon

mutation,

it

is

quite

possible

that

these

other

participants could affect the p53 protein in such a way that
it would not function properly.

For example, if the WAFl DNA
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sequence was altered, a normal p53 protein could not bind and
the

WAFl protein would not be

produced.

In

this

way,

uncontrolled cell growth would result independent of mutations
of the normal p53 protein. Still, the p53 protein is involved
in this situation, even though it is not directly affected.
Lastly, an alternative that might help explain the low
mutation rate of p53 in gliomas is that p53 is simply not
involved to a great extent. Perhaps there are mechanisms that
are entirely independent of p53 that account for the other
percentage

of the gliomas not accounted for under p53 's
For

parameters.

instance,

very recently,

another

tumor

suppressor gene has been isolated as the Multiple Tumor
Suppressor

1

(MTSl)

(Kamb et al.,

1994) .

This gene is

localized to the short arm of human chromsome 9, and encodes
pl6,

an inhibitor of cyclin-dependent kinase 4.

In this

manner, MTSl is similar to WAFl in its cell cycle mechanism of
tumor suppression. This MTSl could be a valuable alternative,
but it is equally important not to abandon p53, for there are
many of its co-participants that have not been studied in
enough detail or possibly not even discovered yet.

Also, p53

has much higher mutation rates in other cancers besides
gliomas, so its application may simply not be as widespread as
originally

proposed.

For

this

reason,

perhaps

p53

is

applicable to .certain cancers and tumor suppressors such as
MTSl are better suited in other scenarios. Still, p53 remains
the focal point of the tumor suppressor model, for it has
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become increasingly eminent as a diagnostic indicator of
familial cancer syndromes and as a potential candidate for
gene therapy techniques.
Future Research

The p53 tumor suppressor gene is an important participant
in a variety of cancers.

Mutations of this gene produce a

protein product that is inactive, and neoplasia results.
Especially in cancers such as breast, colorectal, and lung,
the high p53 mutation rate indicates that it is a primary
target for successful tumorigenesis. Reintroduction of wild
type p53 protein into these tumors by gene therapy techniques
could prove to be a very effective treatment in the future.
However,

in

the

case

consistently lower.

of

gliomas,

the

mutation

rate

is

The low mutation rate of p53 in gliomas

indicates that p53 may not be the most universal indicator of
malignancy grades.

Also, if gene therapy with normal p53 is

successfully done in gliomas, the low mutation rate indicates
that it may be less effective than in other cancers.

It is

always possible that p53 may not be prevalent in gliomas, but
high protein accumulation indicates otherwise.

Despite low

mutation rate, the accumulation of wild-type p53 protein
(Rubio et al., 1993; Lang et al., 1994; Van Meir et al.,1994)
indicates that p53 is important -in some aspect in gliomas that
may account for the other percentages.

While needed research
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continues on p53 gene therapy, perhaps a coordinate focus of
p53 research should be on the other participants in the p53
tumor suppressor model.

In this way, while methods of p53

gene therapy are explored, insight into the other co-factors
of p53 will make the therapy that much more effective when it
is perfected.
Areas that warrant consideration include the various
proteins

associated with the p53 protein.

It would

be

interesting to study the mechanism and timing by which the p53
protein is shuttled from its formation in the cytoplasm to its
function in the nucleus, and whether that mechanism is protein
dependent or independent.
(1993), Lang et al.

In the studies of Rubio et al.

(1994), and Van Meir et al.

(1994), some

of the wild-type p53 protein accumulation could have been
detected in the cytoplasm after translation.

The protein is

normal, but perhaps there is a defect in its mechanism for re
entry into the nucleus.

Therefore, it tests normal, but its

function cannot be exerted and tumors develop.
Other proteins that could be studied are the ones that
are located in the nucleus where the wild-type p53 protein
performs its function.

As postulated by Maxwell and Roth

(1993), there may be other proteins that are required to bind
to the p53 protein in a complex before it can bind correctly
to DNA for transcription.

These proteins may somehow be

altered, and therefore even normal p53 cannot bind properly
and suppress glial tumors.

If this is the case, then wild-
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type p53 protein may accumulate, but it does not perform its
function because of problems with its associated DNA-binding
proteins.

Along the same lines, there may be proteins such as

mdm-2 that bind to the p53 protein and negatively regulate it
so that it cannot perform its function.
levels of the wild-type product,

There may be elevated

but associated proteins

prevent the p53 protein from binding to the correct sequences
and stopping the cell cycle.

In the studies done with high

protein accumulation with low mutation rate,
overexpression of the mdm-2 product.

there was no

This does not mean that

there are not other negative-regulator proteins of p53 that
have not been discovered yet.
Perhaps one of the most promising areas of p53 research
is the effect of downstream effector genes such as WAFl.

If

the WAFl gene is mutated, then the function of the p53 protein
cannot be executed despite normal p53 protein accumulation,
for the p53 protein does not have a correct DNA sequence to
bind properly.

This would account for the high wild-type .p53

protein accumulation that does not seem to be exerting its
tumor

suppressor effect.

More tests should be done to

sequence the WAFl gene, and muuation analysis would indicate
if it was a frequently altered participant in gliomas.

If so,

this would account for the formation of tumors without p53
gene mutations.

Perhaps the WAFl gene is not mutated, but

somehow does not interact properly with the CDK's to prevent
cell cycle progression in response to DNA damage.

All of
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these possibilities lend support to numerous alternatives that

could be influential in the enigmatic p53 model of tumor
suppression in gliomas.

If a gene such as WAFl is involved

more extensively in gliomas than p53 mutations, perhaps WAFl
could

be

techniques.

used

along

with

p53

in

future

gene

therapy

Also, there would be questions about why WAFl is

more influential in gliomas and p53 mutations are more evident
in other cancers.
with WAFl

It should be noted that all of these tests

are based on the assumption that WAFl

is the

principal effector by which p53 affects the cell cycle.
These are some of the many possiblities that could help
explain the difference in p53 mutation rate and alternative
development of tumors in gliomas.

Any information obtained

from these suggested areas of future research could be used in
other cancers in addition to gliomas.

Conclusion
Tumorigenesis involves the abnormal growth of cells due
to the interaction of two distinct processes, activation and
inactivation.

There is activation of oncogenes that allows

for uncontrolled proliferation and inhibits differentiation.
Equally

essential,

there

is

the

inactivation

of

tumor

suppressor genes that normally serve to inhibit uncontrolled
growth and promote differentiation.

One of the most important

tumor suppressor genes currently studied is the p53 gene,
located on the short arm of the human chromosome 17.

However,

it took many years of research for this gene to attain
recognition for its part in the vastly changing tumorigenesis
scheme of gliomas.
P53 was originally postulated to be a viral protein, and
later a nuclear oncoprotein or oncogene.

Due to subsequent

experiments and an already established tumor suppression model
in the Rb gene,
perspective.

p53 began to be viewed from a different

It became clear that the p53 gene was capable of

such characteristics as cell cycle arrest in Gl phase of the
cell cycle.

Other characterizations such as these made the

p53 gene a likely tumor suppressor gene candidate.

However,

it was not until it was correlated,

due to advances in

cytogenetics

with

and

molecular

genetics,
68

chromosome

17
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abnormalities that its true function became clear.

Chromosomal abnormalities, specifically chromosome 17,
had been studied for many years, beginning with colorectal
carcinoma, lung carcinoma, and eventually gliomas.

It was

discovered that the p53 gene was located and associated with
these same chromosome 17 aberrations.

The role of p53 in a

variety of cancers as a tumor suppressor gene became evident,
for inactivation of this gene by mutation resulted in a
variety of neoplasms.

In fact, the mutated p53 gene product

could be used to indicate the malignancy grade of gliomas,
such as the difference between anaplastic astrocytomas (WHO
grade III) and glioblastoma multiformes (WHO grade IV).
A problem arose when experiments began to show that the
p53 mutation rate was much lower in gliomas than in other
types of cancers.
appears

that

Despite its practical applications,

other mechanisms

present in gliomas,
accumulation is high.
the p53 gene,

besides

p53

mutations

it
are

for the amount of wild-type protein
These methods could be independent of

but it is more likely that these are p53-

dependent mechanisms, such as the WAFl gene.

Despite the

different results of experimen�s illustrating the role of p53
in gliomas, it is quite clear that the many aspects of p53 are
essential to the future of cancer research,

whether it be

through familial cancer syndromes or gene therapy.

The p53

tumor suppressor gene is a leader in the evasive fight against
cancer, especially with the alarmingly malignant glioma.
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